Jan 30, 2019 4:05pm EST SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Jan 22, 2019 8:45am EST SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
Nov 13, 2018 9:05am EST SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
Oct 23, 2018 9:00am EDT SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
Oct 15, 2018 9:26am EDT SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
